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Nicotine, a major alkaloid, is present in tobacco products as well as in smaller 
amounts in potatoes, tomatoes, and eggplants. Although it is the addictive compound in 
cigarettes, nicotine is believed to play a protective role in neurodegenerative disorders 
such as Parkinson’s disease. Researchers have found that the short-term administration of 
nicotine may help improve the memory process by reducing oxidative stress in the brain. 
Our studies have shown that, by blocking Fenton’s reaction, nicotine is able to inhibit 
free radical generation, so this research has focused on the antioxidant properties of 
nicotine. The cell lines of the alveoli, blood brain barrier, liver, and Chinese hamster 
ovaries were treated with 1mM of nicotine for 2 hours, and then the reactive oxygen 
species were measured. Results showed that the decrease in reactive oxygen species 
might be due to the inhibition of Fenton’s reaction by metal chelation. The metal 
chelating property of nicotine was tested and its chelating ability was confirmed. 
Moreover, a study was made of the effects of nicotine on glutathione levels in alveolar 
cells that were treated with 0.4mM tert-butyl hydroperoxide for 3 hours. Results showed 
that nicotine prevented the depletion of glutathione levels in the tertiary butyl hydro 
peroxide treated group. These findings indicate that nicotine in both conventional and 
electronic cigarettes may alleviate symptoms of some neurodegenerative disorders by 
reducing oxidative stress caused by free radicals. However, the smoke from the burning 
tobacco in conventional cigarettes contains many harmful carcinogenic compounds in 
addition to nicotine. This is not the case with e-cigarettes, which also contain nicotine, 
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 1. INTRODUCTION 
 
Nicotine, one of the most potent alkaloids found in significant amounts in tobacco 
leaves, is also present in lower levels in potatoes, tomatoes and eggplants. Chemically, 
nicotine, a tertiary amine, is composed of pyridine and pyrrolidine rings. It exists as two 
enantiomers in tobacco, levorotary (S) enantiomer and dextro (R), with S being 
predominant (>99%).
1 
(Figure 1.1). At a half-life of approximately 2 hours, it becomes 
extensively metabolized into cotinine (a major metabolite of nicotine).  
                
Figure 1.1  Enantiomers of nicotine. 
1.1 PHARMACOLOGY OF NICOTINE 
While nicotine, a para sympathomimetic alkaloid, can easily be absorbed by the 
lungs and readily pass through the blood brain barrier (BBB), its absorption through 
biological membranes is pH dependent.
2
 Normally, nicotine is a weak base with a pKa of 
8.0.
3
 In an acidic environment, it becomes ionized and is not able to rapidly permeate 
biological membranes. Smoke from flue-cured tobacco (found in most conventional 
cigarettes) is acidic; hence it cannot permeate through the buccal membrane.
4






other hand, smoke from air-cured tobaccos (found in cigars and some European 
cigarettes) is more alkaline (~pH 6.5), with a considerable amount of non-ionized 
nicotine that can readily permeate biological membranes. Researchers have found that the 
pH of cigarette smoke particulates is more alkaline, with a larger portion of the nicotine 
not being ionized, thereby facilitating rapid pulmonary absorption.
5
 The nicotine from 
tobacco smoke is rapidly absorbed into the small airways and alveoli of the lungs, and 
then immediately enters and circulates in the blood.
6
 The large surface area of the alveoli 
and the small airways in the lungs, along with the lung fluid (pH 7.4), facilitate rapid 
absorption of high amounts of nicotine by the membranes.  
Nicotine, after entering pulmonary circulation, rapidly enters the brain
7
 and then 
stereo-selectively binds to the nicotinic cholinergic receptors (nAChRs).
8
 Stimulation of 
these receptors releases various neurotransmitters, including dopamine.
9
 Dopamine, an 
important neurotransmitter that is responsible for the nicotine dependence and sensitivity 
mediated by the α4β2 nAChRs. α4 subunit, is an important determinant of sensitivity to 
nicotine.
10
 On the other hand, the β2 subunit mediates the release of dopamine and 
controls behavior.
11
           
Studies have indicated that nicotine plays a potential role in the generation of 
reactive oxygen species, while some papers have shown its protective role in patients 
with brain disorders such as Parkinson’s, Alzheimer’s, and schizophrenia.12 Parkinson’s 
disease is the loss of neuromelanin containing dopamine from the substantia nigra pars 
compacta due to the further catalyzation by iron of the biochemical pathways of the 
neurotoxins.
13





resulted in improvements in attention and information processing by Down’s syndrome 
patients, when compared to healthy controls.
14
 Researchers have also found that the 
chronic administration of nicotine might be beneficial to patients with dementia, where it 
acts as a cognitive enhancer.
15
 These beneficial effects of nicotine might be due to its 
antioxidant mechanism that is primarily related to the presence of free iron.
16
 Even 
though some research has indicated that cigarette smoking may have a potential 
advantage in treating neural disorders, like Parkinson’s, it cannot achieve its full potential 
because of the dangerous toxicities associated with burning tobacco.
17
 
With the advancement of technology, electronic cigarettes (e-cigarettes) have 
been introduced into the market and have become extremely popular among young 
people. In fact, sales of e-cigarette have increased from 50,000 in 2008 to 3.5 million in 
2012.
18
 They are considered to be a potential replacement for conventional cigarettes, 
which are  associated with toxicities that are extremely carcinogenic. As nicotine from e-
cigarettes enters the pulmonary circulation via the alveolar cells, the focus was on the 
role of nicotine in this cell line. 
1.2 OXIDATIVE STRESS 
Maintaining a balance between oxidants and antioxidants is a challenge for any 
living system in virulent environmental conditions, and a shift in balance could result in 
accumulation of reactive oxygen species (ROS) that further generates “oxidative stress.” 
ROS result from many endogenous and exogenous sources, such as inflammatory cells, 








 1.2.1. Chemistry of ROS. Superoxide anion is considered as a primary ROS and 
it is generated as a consequence of either a metabolic process or by activation of oxygen 
by irradiation. These primary ROS will react with the other molecules to generate a 
secondary ROS via an enzyme or metal catalyzed process.
20
 The superoxide anions 
generated undergo a dismutation reaction in the presence of a superoxide dismutase 
(SOD) enzyme, converting it into hydrogen peroxide and oxygen (Figure 1.2).  
     
 
Figure 1.2 Dismutation reaction of a superoxide anion. 
Redox active metals are known to closely link with the generation of free 
radicals.
21
 The redox state of a cell is largely linked to an iron redox couple, and is 
maintained under strict physiological conditions.
22
. However under excessive stressful 
conditions, an excess of superoxide releases free iron from enzymes, such as the 
dehydratase-lyase family which has [4Fe-4S] clusters
23
. Iron that is released participates 
in Fenton’s reaction (Figure 1.3), promoting generation of hydroxyl radicals as a 
secondary ROS.
24, 25, 26, 27
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These generated hydroxyl radicals are highly reactive and have a half-life of less 




which explains its highly reactivity towards anything in 
its vicinity. If hydroxyl radicals are generated close to DNA, they could react with DNA 
and result in DNA mutations, thereby causing cancer.
29
 The hydroxyl radicals that are 
generated, not only react with DNA, but also with polyunsaturated fatty acid residues of 
phospholipids (main component of the cell membrane), which are extremely sensitive to 
oxidation
30, 31 
and result in lipid peroxidation (Figure 1.4).  
 
           






 1.2.2. Antioxidants and Their Role. In order to defend the body against the 
various ROS that are generated, a living system produces various antioxidants that can be 
either enzymatic or non-enzymatic. The modern way to define an antioxidant in a living 
system is “any substance that delays, prevents, or removes oxidative damage to a target 
molecule.” 33  
Antioxidants can be broadly classified into  
a. Enzymatic antioxidants: 
 Superoxide dismutase (SOD) 
 Catalase (CAT) 
 Glutathione reductase (GR) 
 Glutathione peroxidase (GPx) 










b. Non-enzymatic antioxidants: 
 Thiol antioxidants  
- endogenous thiols - glutathione (GSH), thioredoxin, lipoic acid, etc. 
- exogenous thiols - N-acetyl cysteine (NAC), N-acetyl cysteine amide 
(NACA), etc. 
 Vitamins - E and C (ascorbic acid). 
 Metal chelators - Lactoferrin. 
 Other antioxidants - Carotenoids, Flavonoids, etc. 
One of various non-enzymatic antioxidants, GSH is an important and major thiol 
antioxidant that is synthesized in the living system in order to defend against ROS. GSH, 
a tripeptide with a gamma peptide linkage between the cysteine amine group, is attached 
by normal peptide linkage to a glycine and the carboxyl group of the glutamate side-
chain
34 
(Figure 1.6). Most of the available GSH is kept in reduced form by glutathione 
reductase (GR) by the conversion of oxidized glutathione (GSSG). When there is 
oxidative stress, GSH is depleted, although it is constantly replenished by cells. In severe 
oxidative stress conditions, the rate of replenishment will not match the rate of depletion, 
resulting in excessive ROS pooling in cells and causing damage that may range from 
severe DNA damage to cell death.  
 





GSH antioxidant capability is due to the sulfur atom which can easily accommodate the 
loss of a single electron
35
. GSH antioxidant activity can be simplified as: 
 
 
The protective roles of GSH in oxidative stress
36 
are due to (i) cofactor (such as 
glutathione peroxidase and glutathione transferase) in detoxifying enzymes against 
oxidative stress, (ii) scavenge hydroxyl radical and singlet oxygen directly. Thus, GSH 
along with various enzymatic antioxidants maintains the balance between oxidants and 
pro-oxidants and protects cells from oxidative stress. 
Many studies have revealed that cigarette smoking generates excessive free 
radicals that cause various diseases, including cancer.
37, 38, 39
 Since the major ingredient in 
cigarettes is nicotine, a highly addictive component, smokers find it extremely difficult to 
quit. Even though a number of researchers are convinced as to the extent of the  role of 
nicotine in oxidative stress, considerable research is still needed to determine its 
influence on our health and well-being. 
Within tobacco smoke, (apart from nicotine), there are nearly 4,000 other 
compounds in various proportions. Studies have revealed that smoking tobacco generates 
numerous carcinogens, which are the major causes of various types of cancers, as well as 
promoting several oxidative stress disorders. When cigarettes are burned, Benzo[a]pyrene 
forms and enters the body. In the presence of the ubiquitous P-450 enzyme system, it is 
converted into (+) benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide, a known potent 
carcinogen
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Figure 1.7 Conversion of benzo[a]pyrene. 
As stated earlier the addictive properties of nicotine make quitting smoking a 
challenge for many people. With the introduction of e-cigarettes to the market, it is 
possible that smokers will benefit by using them instead of conventional cigarettes.  The 
main addictive component, nicotine, is in both cigarettes, but the e-cigarettes do not have 
the toxic materials which promote carcinogens that accompany the nicotine in 
conventional cigarettes. Although various nicotine replacement therapies are marketed, 
such as nicotine patches and gum, these have not been successful because circulation of 
the nicotine from these replacements is slow and administration of sufficiently high levels 
of nicotine cannot be achieved. Because nicotine enters the body through alveolar cells, it 
is important to know the effects of nicotine on these cells, so a study was made of the role 













2. AIM OF STUDY 
 
The primary aim of this study was to determine the role of nicotine in oxidative 
stress, particularly in the lung cells, where nicotine initially enters and circulates 
throughout the body. 
And also an exploration was made of the potential role of nicotine as an antioxidant 


















High performance liquid chromatography (HPLC) grade solvents were obtained 
from Fisher Scientific, Waltham, MA. Soybean trypsin inhibitor was obtained from Life 
Technologies 
TM
, New York, NY.  All other chemicals were obtained from Sigma 
Aldrich, St. Louis, MO.  
3.2. CELL CULTURE 
3.2.1 Cell Lines.  
3.2.1.1. Human liver hepatocellular carcinoma cells (HepG2). These cells were 
obtained from ATCC, Manassas, VA. They are adherent, epithelial-like cells that grow as 
monolayers and in small aggregates. They were derived from 15-year old male 
adolescent livers with differentiated hepatocellular carcinoma. 
3.2.1.2. Chinese hamster ovary cells (CHO). These cells were obtained from 
ATCC, Manassas, VA. They are epithelial cells that grow as an adherent monolayer in a 
culture. This is the simplest and most popular cell line for carrying out screening studies.  
3.2.1.3. Blood brain barrier cell line (BBB). The hCMEC/D3 cell line was used 
as a model for the human BBB. They were obtained as a gift from Prof. Pierre-Olivier 
Couraud. It was derived from human temporal lobe micro vessels that were isolated from 





3.2.1.4. Alveolar cell line (A549). These cells were purchased from ATCC, 
Manassas, VA. They are adherent, epithelial cells that grow as monolayers. They were 
derived from a 58-year old male Caucasian’s lungs. 
3.2.2. Culturing Cell Lines. 
3.2.2.1. Culturing HepG2, CHO, and A549 cell lines.  HepG2, CHO, and A549 
cells were grown in a F-12: DMEM 1:1 nutrient media that was obtained from Sigma 
Aldrich, St.Louis, MO. A complete media was prepared with 10% fetal bovine serum 
(FBS), 2% pencilin, and 6.25ml of L-gultamine for a 500ml media. All cells from the 
liquid nitrogen were transferred to different 75cm
2 
corning flasks, which already 
contained 10ml of the complete media. These flasks were incubated with 5% CO2 at 37
o 
C. The media was changed every 48 hours until each flask reached 90% confluence. 
Once a flask was full, the cells were treated with 2ml of 1X Trypsin-EDTA and incubated 
for 3 minutes. Finally, trypsin action was blocked by using a soybean trypsin inhibitor. 
3.2.2.2. Culturing BBB cells. BBB cells were obtained as a gift from Prof. 
Pierre-Olivier Couraud. They were grown in an EBM-2 basal media obtained from  
Lonza. A complete media was prepared by adding 5ml of penicillin- streptomycin, 
12.5ml of FBS, 125µl of VEGF, 125µl of IGF, 125µl of EGF, 50µl of hydrocortisone, 
5ml of 1M hepes buffer, and 5µl of bFGF to 500ml of basal media. The cells were 







3.3.  EXPERIMENTAL PROCEDURES 
3.3.1. Reactive Oxygen Species (ROS) Assay. ROS was measured in four 
different cell lines: BBB, CHO, HepG2 cells, and A549 cells. Cellular ROS were assayed 
in a Costar 96-well plate by using a Fluo-star Optima plate reader, in fluorescence mode, 
with an excitation wave length of 485 nm and an emission wave length of 520 nm, with 
2’, 7’-dichloro-dihydro-fluorescin diacetate (DCHF-DA) as a fluorescent dye (Figure 
3.1). This could be enzymatically converted to the highly fluorescent compound, DCF, in 
the presence of ROS. Cells from the BBB, HepG2, CHO, and A549 cells were used to 
test the role of nicotine in generating ROS. In this test, the wells were seeded with 15,000 
cells/well, with five replicates of each group. After 12 hours of seeding the cells, the 
media was replaced by DCFH-DA dye with a 40 µM concentration, prepared in a serum-
free media, and then incubated for 1 hour. After 1 hour, a media with a dye was replaced 
by various concentrations of nicotine (1µM, 10µM, 100µM, 500µM, 1000µM) that had 
been prepared in a serum-free media. Cells were incubated with nicotine for 2 hours and 
the fluorescence was measured using a Fluo-star optima plate reader. 
3.3.2. Cell Viability Assay. A  cell viability assay was made of the A549 cell line 
by using a calcein AM dye, a non-fluorescent, hydrophobic compound, that easily 
permeates intact live cells. In the presence of esterases, it was converted to calcein, a 
hydrophilic, strongly fluorescent compound (Figure 3.2). Cell viability was carried out in 
a 96-well plate with 15,000 cells/well with five replicates. After seeding the cells in 
wells, the plates were incubated for 12 hours and then the cells were dosed with various 
concentrations of nicotine (2mM, 4mM, 5mM, 6mM) that had been prepared in a serum-





loaded with 2 µM of calcein AM dye, after removing the nicotine for 30 minutes. After 
30 minutes of incubation, the plates were read using a Fluo-star Optima with 485 nm as 
the excitation wave length and 530 nm as the emission wave length. The fluorescent 














 Figure 3.2 Cell Viability assay using Calcein AM dye. 
 
3.3.3. Metal Chelating Capabilities. Iron chelating capabilities of samples were 
determined by the method of Dinis et al.
42
 A solution containing 20µl of the sample and 
0.38ml of water was added to 0.05ml of 2mM Fecl2. The mixture was vortexed 
vigorously for 1 minute, and reaction was initiated by the addition of 0.2ml of 5mM of 
ferrozine [3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine-4’,4”-disulphonic acid sodium salt] 
and 3.35ml of ethanol. The solution was incubated for 10 minutes and its color was 
monitored at 562 nm. The Fe
+2
 chelating activities of the samples were calculated as 
   % Chelation = [(Ao – A1 )/Ao ] x 100 





3.3.4. Glutathione (GSH) Measurement. Cellular levels of GSH were 
determined by using the method developed by RP-HPLC according to the method 
developed in our laboratory, Winters et al.
43
 The HPLC system consisted of a 
FinniganTM Spectra System with a SCM 1000 vacuum membrane degasser, a 
FinniganTM Spectra System P2000 gradient pump, a FinniganTM Spectra System 
AS3000 autosampler, and a FinniganTM Spectra System FL3000 fluorescence detector 
(λex = 330nm and λem=376nm) (Thermo Electron Corp., Austin, TX). The high 
performance liquid chromography (HPLC) column (Column Engineering, Ontario, CA) 
was 100 x 4.6 mm I.D and was packed with C18 packing material. Quantitation of the 
HPLC peaks was done using a Chromatopac Model CR 601 integrator (Shimadzu). The 
mobile phase was 30% water and 70% acetonitrile, and was adjusted to a pH 2 with 
acetic acid and O-phosphoric acid. The NPM (N-(1-pyrenyl)maleimide) derivatives of 
GSH were eluted from the column isocratically at a flow rate of 1ml/min. A549 cells 
were seeded in a 75 cm
2
 flask and placed in an incubator to obtain 90% confluence, and 
then divided into four groups. Group A was control, Group B was nicotine, Group C was 
t-BHP, and group D was nicotine with t-BHP. Groups B and D were treated with nicotine 
in a serum-free media for 2 hours. After 2 hours of incubation, the Group B media was 
replaced with a serum-free media while Group C and Group D were treated with 0.4mM 
t-BHP for 3 hours and then incubated. Finally, cells are trypsinized and homogenate were 
prepared in a serine borate buffer (SBB) (100mM of Tris-HCl, 10mM of boric acid, 5mM 
of L-serine, 1mM of DETAPAC, pH 7.5). 50µl of this homogenate was added to 200µl 
of HPLC water and 750µl of NPM (1mM in acetonitrile). NPM (the derivatizing agent) 





incubation for 5 minutes, 2N HCl was added to the reaction mixture to stop the reaction. 
Derivatized samples were filtered through a 0.45µl acrodisc and then injected into a 
HPLC column. This adduct was detected by a fluorescent detector (Figure 3.4) that was 
connected to a HPLC column. Quantitation of the HPLC peaks was done using a 
Chromatopac Model CR 601 integrator. 
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Figure 3.4 Chromatogram of A549 cells homogenate showing glutathione peak after 
derivatizing. 
3.3.5. Protein Determination. The Bradford method was used to measure the 
protein levels of the samples using Coomassie Blue (Bio-Rad). The concentrated dye was 
diluted 1:5 (v/v) using SBB. 25µl of homogenate, that had been prepared in SBB, was 
mixed with 1ml of diluted dye and incubated for 5 minutes at room temperature. Various 
concentrations of a protein standard solution were prepared from a stock solution of 
bovine serum albumin (1mg/ml). To 25µl of stock solution, 1ml of diluted dye was 
added, and then the solution was incubated for 5 minutes. After incubation, the 
absorbance of the samples and the standard solution were measured at 595 nm. The 
unknown protein concentrations of the samples were calculated from a standard curve. 
Minutes









































































































































































































































































































3.3.6. Malondialdehyde Assay. The amount of malondialdehyde (MDA) is one 
of the important parameters used to determine the degree of lipid peroxidation.  350 µl of 
cell homogenate were mixed with 100µl of 500ppm butylated hydroxy toluene (BHT), 
and then 550µl of 10% trichloroacetic acid (TCA) were mixed in pyrex tubes and boiled 
for 30 minutes.  After the tubes were cooled in ice, they were centrifuged at 2,500 RPM 
for 5 minutes. 500µl of a saturated thiobarbituric acid (TBA) solution were mixed with 
500µl of supernatant. After boiling again for 30 minutes (results in adducts, Figure 3.5), 
500µl of this supernatant were placed in a test tube that contained 1.0ml of n-butanol. 
This mixture was vortexed for 5 minutes and then centrifuged for 5 minutes at 1,000 
RPM. 200µl of the supernatant were placed in 96-well plates and then analyzed by using 
a fluorescent plate reader with an excitation wave length of 510nm and an emission wave 

































3.3.7. Statistical Analysis. The data were given as the Mean ± SD. The one-way 
analysis of variance (ANOVA) and Tukey’s multiple comparison tests were used to 
analyze the significance of the differences between the control and the experimental 

















4.1. GENERATION OF REACTIVE OXYGEN SPECIES (ROS) AND EFFECT 
OF NICOTINE 
ROS were assayed in the cells of the BBB, HepG2, CHO, and A549. The cells 
were pretreated with DCFH-DA dye for 1 hour and then post treated with nicotine. 
Results indicated that all four cell lines did not cause any ROS when treated with 
different concentrations of nicotine (0.5µM, 1µM, 10µM, 100µM, 500µM). In fact, at 
higher concentrations, the nicotine significantly inhibited the generation of ROS in all 
cell lines, except in the CHO cells (Figures 4.1- 4.5). 
4.2. CYTOTOXICITY OF NICOTINE 
A cell viability assay was made of the alveolar cell line (A549). The cells were 
incubated with different concentrations of nicotine (2mM, 4mM, 5mM, and 6mM) for 24 
hours. The results revealed that nicotine acted in a concentration-dependent manner on 
lung cells, but had a no significant toxic effect on the group treated with a 2mM nicotine 
concentration, as compared to the control group. Concentrations (beginning with 4mM) 
showed a significant toxic effect on these cells, as compared to the control group. Results 
are shown in Figure 4.6.  
4.3. METAL CHELATION ASSAY 
Nicotine was shown to have metal chelation properties when it was tested using 
ferrozine. With an increase in the concentration of nicotine, chelation increased 






4.4. GLUTATHIONE (GSH) ASSAY IN THE PRESENCE OF T-BHP AND THE 
EFFECT OF NICOTINE ON GLUTATHIONE IN T-BHP TREATED 
GROUP 
GSH is an important parameter for determining the extent of oxidative stress in 
living systems. A549 cells were treated with nicotine and t-BHP. After incubation, the 
cells were trypsinized and then homogenized for assaying. Results indicated that nicotine 
treatment of the cells did not significantly deplete the GSH levels in the cells, as 
compared to the control. The group treated with t-BHP showed an increase in GSH levels 
when pretreated with nicotine, as indicated in the graphs in Figure 4.8. 
4.5. MALONDIALDEHYDE ASSAY IN THE PRESENCE OF NICOTINE 
MDA is an important parameter for determining the degree of damage to a cell. 
When excessive hydroxyl radicals are formed, they readily react with lipids which results 
in the formation of MDA as an end product. The MDA in A549 cells was measured 
fluorometrically by forming an adduct with TBA. The A549 cells that were treated with 
nicotine for 2 hours did not show any significant increase in MDA, as compared to the 
control, which indicates that nicotine alone may not induce lipid peroxidation in the A549 


































































































Figure 4.1 ROS generation and the effect of nicotine on A549 cells. The cells were 
treated with various concentrations of nicotine (0.1µM, 10µM, 100µM, 500µM, 
1000µM) for 2 hours. 0.4mM t-BHP was used as a positive control and the ROS assay 
was carried out using DCF-DA fluorescence dye. Results are represented as mean ± SD 




























































































Figure 4.2 ROS generation and the effect of nicotine on BBB cells. The cells were treated 
with various concentrations of nicotine (0.1µM, 1µM, 10µM, 100µM, 500µM, 1000µM) 
for 2 hours. 0.5mM t-BHP was used as a positive control and the ROS assay was carried 
out using DCF-DA fluorescence dye. Results are represented as mean ± SD (n=5). * 





























































































Figure 4.3 ROS generation and the effect of nicotine on HepG2 cells. The cells were 
treated with various concentrations of nicotine (0.1µM, 1µM, 10µM, 100µM, 500µM, 
1000µM) for 2 hours. 0.5mM t-BHP was used as a positive control and the ROS assay 
was carried out using DCF-DA fluorescence dye. Results are represented as mean ± SD 



























































































Figure 4.4 ROS generation and the effect of nicotine on CHO cells. The cells were 
treated with various concentrations of nicotine (0.1µM, 1µM, 10µM, 100µM, 500µM, 
1000µM) for 2 hours. 0.5mM t-BHP was used as a positive control and the ROS assay 
was carried out using DCF-DA fluorescence dye. Results are represented as mean ± SD 

















































Figure 4.5 Summary of ROS assay of four different cell lines (A549, BBB, HepG2, 
CHO) with 500µM of nicotine. Graphs indicate percentage of fluorescence in different 
cell lines compared to that of control group. * Indicates significantly different from 




































































Figure 4.6 Cytotoxicity of nicotine on A549 cells. The cells were treated with various 
concentrations of nicotine (2mM, 4mM, 5mM, 6mM) for 24 hours.  A cytotoxicity assay 
was carried out using calcein Am, fluorescence dye. Results are represented as mean ± 







































































Figure 4.7 The metal chelating properties of nicotine. Experiment was carried out using 
various concentrations of nicotine (1µM, 10µM, 100µM, 500µM, 1000µM) with 
ferrozine. Results are represented as mean ± SD (n=4), * Indicates that groups were 
significantly different from each other. # indicates group significantly different from 100 

































































Figure 4.8 GSH levels after t-BHP treatment and the protective effect of nicotine. The 
cells were pretreated with 1mM nicotine (for 2 hours) and then treated with 0.4mM t-
BHP for 3 hours and, finally the GSH was measured. Results are represented as mean ± 






















































Figure 4.9 Malondialdehyde levels after t-BHP treatment and the effect of nicotine. The 
cells were pretreated with 1mM nicotine, treated with 0.4mM t-BHP for 3 hours, and then 
the MDA was measured. Results are represented as mean (n=3). No statistical 














5.  DISCUSSION 
 
Nicotine is a well-known parasympathomimetic alkaloidal drug that acts by 
releasing various neurotransmitters, such as acetylcholine, dopamine, vasopressin, etc. It 
is an addictive stimulant that is present in abundance in various tobacco products. 
Researchers have found that nicotine patch therapy relieves mild cognitive impairment in 
some individuals
44
 while others have used animal models to show that nicotine may be 
protective in familial Parkinson’s disease patients.45 Considering the potential role of 
nicotine in treating various neurodegenerative disorders such as this, a study was made of 
the role of nicotine in oxidative stress by focusing on the alveolar cell line where the drug 
initially enters the body. 
Nicotine was found by a few researchers to have a dual effect on oxidative stress 
in adrenal pheochromocytoma cells (PC12 cells)
45
, while others identified the ability of 
nicotine to alleviate symptoms associated with Parkinson’s disease.46 This study was 
concentrated on the role of nicotine in alveolar, BBB, CHO, and HepG2 cells.  The 
results indicated that nicotine did not produce any ROS, but that higher concentrations of 
nicotine (>500 µM) actually inhibited the generation of ROS, possibly by blocking 
Fenton’s reaction by metal chelation. These findings are in agreement with studies done 
by Bridge MH
47
. All cell lines, except CHO cells, showed significant decreases in ROS 
production at concentrations of 500µM and above, as compared to the control group. 
CHO cells had less sensitivity toward nicotine even in the high concentrations and, 





nicotinic receptor. On the other hand, BBB cells showed greater sensitivity toward the 
500µM nicotine concentration than any other cell line did. 
Nicotine was found to be toxic when higher concentrations were used to treat 
cells. Toxicity was observed in a dose-dependent manner, when treatment was 
administered for 24 hours. Cells showed significantly decreased viability when treated 
with concentrations of more than 2mM of nicotine for 24 hours. Similar results were 
observed when leydig cells were treated with nicotine in various concentrations (from 
1mM to 100 mM) for 24 hours.
48
 The cells experienced death when they were treated 
with 5mM (or higher) concentrations of nicotine for 24 hours, with the death tentatively 
attributed to apoptosis when the caspase 3 pathway was activated.  From this study, we 
concluded that nicotine does act in a dose-dependent manner and that it is also toxic to 
A549 cells when used in concentrations greater than 2mM. 
Given the possibility of inhibiting Fenton’s reaction by using nicotine, a study 
was made of the metal chelating effect of nicotine on iron. Results indicated that, with 
increase in the concentration of nicotine, there was a corresponding increase in metal 
chelation. This suggested that nicotine might be inhibiting Fenton’s reaction by limiting 
the availability of iron, thereby preventing the generation of hydroxyl radicals. These 
properties of nicotine, and its ability to cross the BBB, explain its protective role for 
Parkinson’s disease. In Parkinson’s disease, dopamine becomes oxidized in the presence 
of the MAO-B enzyme, resulting in the generation of hydrogen peroxide as a byproduct.
5
 







Figure 5.1 Role of Iron in progression of Parkinson’s disease49 and possible protective 
role of nicotine. 
Since nicotine did not produce any ROS, the impact of nicotine on GSH levels 
was studied, and the potential of nicotine as an antioxidant was tested. The groups treated 
with nicotine alone did not show any significant decrease in GSH levels, when compared 
to that of the control group. However, the group pretreated with nicotine for 2 hours and, 
finally, with t-BHP for 3 hours, showed increased levels of GSH when compared to the 
group treated with t-BHP only. This result suggested that nicotine might have some 
protective role, in terms of oxidative stress, by preventing Fenton’s reaction and, thereby, 
impeding the depletion of GSH levels in the cells.  
Also, the role of nicotine in lipid peroxidation was reviewed. Results showed that 
nicotine did not cause any lipid peroxidation when treatment was for 2 hours, and there 





was no significant difference when results were compared to those of the control group. 
This suggested that nicotine, when used as treatment for short periods of time, did not 
produce any hydroxyl radicals. 
In summary, nicotine did not produce free radicals in A549 cells, BBB cells, 
HepG2 cells, and CHO cells; instead, it had a protective role by inhibiting generation of 
ROS. The GSH assay indicates that nicotine protects the cells from oxidative stress, 
possibly blocking Fenton’s reaction by chelating the free iron and, thereby, preventing 


















These research findings suggest that nicotine does not generate ROS in alveolar, 
BBB, CHO and HepG2 cell lines, nor does it cause oxidative stress at the concentrations 
used (1µM, 10µM, 100µM, 500µM). In addition, nicotine does appear to prevent the 
depletion of GSH in the presence of a free radical inducer, thereby protecting cells from 
oxidative stress and, finally, death of the cells. The ability of nicotine to chelate iron 
(required for Fenton’s reaction) may help explain how it inhibits free radical generation 
and alleviates symptoms (and possibly progression) of various neurodegenerative 
diseases. Because e-cigarettes contain nicotine, without the dangerous toxicities 
associated with burning tobacco, it is beneficial and may be a viable alternative to 
conventional cigarettes. Additional research is needed to completely understand the 
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